ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,459.10
1.11%
US Tech 100
18,522.40
1.05%
다우존스 지수
40,589.34
1.64%
Bitcoin
67,883.66
-0.04%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Regeneron Pharmaceuticals Inc (REGN)

  7. Regeneron Pharmaceuticals Inc (REGN) 뉴스

REGN Regeneron Pharmaceuticals Inc

1,078.63
14.44 (1.36%)
27 7월(7) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Regeneron Pharmaceuticals Inc REGN 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
Upgrade Icon
14.44 1.36% 1,078.63 07:01:24
개장가 저가 고가 종가 전일 종가
1,067.54 1,073.76 1,091.305 1,078.63 1,064.19
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
13/07/202405:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/07/202420:00EDGAR2Form 8-K - Current report
03/07/202414:00GLOBEDupixent® (dupilumab) Approved in the European Union as the..
03/07/202401:53PRNUSKuehn Law Encourages Investors of Regeneron Pharmaceuticals,..
28/06/202420:00GLOBEOdronextamab Recommended for EU Approval by the CHMP to..
28/06/202405:05GLOBERegeneron to Report Second Quarter 2024 Financial and..
27/06/202406:30GLOBEDupixent® (dupilumab) Positive Phase 3 Data in Children 1 to..
18/06/202405:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/06/202419:10GLOBEUpdated Linvoseltamab Data Showcase Continued Deepening of..
15/06/202405:26EDGAR2Form 144 - Report of proposed sale of securities
14/06/202405:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/06/202406:04EDGAR2Form 144 - Report of proposed sale of securities
13/06/202405:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/06/202405:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/06/202420:00GLOBEKevzara® (sarilumab) Approved by FDA for the Treatment of..
11/06/202405:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/06/202405:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/06/202405:12EDGAR2Form 144 - Report of proposed sale of securities
06/06/202405:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/06/202405:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/06/202403:24EDGAR2Form 144 - Report of proposed sale of securities
04/06/202405:36EDGAR2Form 144 - Report of proposed sale of securities
31/05/202414:05GLOBEDupixent® (dupilumab) Recommended for EU Approval by the..
31/05/202414:00GLOBEUpdate on FDA Priority Review of Dupixent® (dupilumab) for..
30/05/202405:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/05/202420:15PRNUSBiohaven Doses First Patient with its Novel Trop-2 Directed..
29/05/202405:29EDGAR2Form 144 - Report of proposed sale of securities
24/05/202406:03GLOBEPromising Anti-tumor Activity of Novel Costimulatory..
23/05/202405:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/05/202405:10EDGAR2Form 144 - Report of proposed sale of securities
21/05/202403:15GLOBEDupixent® (dupilumab) Late-Breaking Data from NOTUS..
18/05/202406:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/05/202405:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/05/202405:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/05/202402:45GLOBEMore than $9 Million Awarded to High School Scientists and..
16/05/202407:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/05/202405:21EDGAR2Form 144 - Report of proposed sale of securities
13/05/202414:00GLOBEDupixent® (dupilumab) sBLA Accepted for FDA Priority Review..
08/05/202419:00GLOBELatest DB-OTO Results Show Dramatically Improved Hearing to..
07/05/202405:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/05/202405:05GLOBERegeneron Announces Investor Conference Presentations
02/05/202419:30GLOBERegeneron Reports First Quarter 2024 Financial and Operating..
29/04/202420:00GLOBEEYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO..
25/04/202420:00GLOBERegeneron and Mammoth Biosciences Collaborate to Pursue..
24/04/202423:05GLOBERegeneron to Showcase Progress in Advancing Novel..
23/04/202406:54GLOBERegeneron to Highlight Advances in Genetic Medicine Research..
16/04/202420:18IHMARKETNEWSEricsson Soars with 66% Net Profit Growth; Live Nation Under..
11/04/202420:24IHMARKETNEWSCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’..
08/04/202405:00GLOBELinvoseltamab Pivotal Data Presented at AACR Reinforce High..
02/04/202405:05GLOBERegeneron to Report First Quarter 2024 Financial and..

최근 히스토리

NASDAQ
REGN
Regeneron Pharmaceuticals
AMEX
STLV
iShares Factors US Value...
NASDAQ
JWEL
Jowell Global
HITB
XRPBTC
Ripple
COIN
GIFTEUR
BIT
ADB
AEROPORTO GUGLIELMO MARC...
ASX
ANVHH
Ausnet Services Holdings...
ASX
AJQDA
Armour Energy
SUSHI
GTONETH
Graviton
FX
PHLKEYPR
Philippines Key Policy R...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유